• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    6/5/24 12:31:03 PM ET
    $BGXX
    $CCM
    $CSBR
    $CVRX
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $BGXX alert in real time by email

    Gainers

    • ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million.
    • Rezolute (NASDAQ:RZLT) stock moved upwards by 23.91% to $5.76. The company's market cap stands at $231.2 million.
    • Bright Green (NASDAQ:BGXX) shares rose 23.07% to $0.36. The company's market cap stands at $69.0 million.
    • Champions Oncology (NASDAQ:CSBR) shares increased by 22.42% to $5.65. The company's market cap stands at $76.8 million.
    • Kineta (NASDAQ:KA) shares moved upwards by 22.11% to $0.53. The market value of their outstanding shares is at $6.4 million.
    • CVRx (NASDAQ:CVRX) stock moved upwards by 21.57% to $7.89. The market value of their outstanding shares is at $170.3 million.

    Losers

    • SILO Pharma (NASDAQ:SILO) stock decreased by 36.5% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.0 million.
    • Concord Medical Services (NYSE:CCM) shares fell 30.01% to $1.47. The market value of their outstanding shares is at $63.8 million.
    • FibroBiologics (NASDAQ:FBLG) stock declined by 20.56% to $7.15. The market value of their outstanding shares is at $233.9 million.
    • Cue Health (NASDAQ:HLTH) shares decreased by 19.1% to $0.05. The market value of their outstanding shares is at $7.9 million.
    • GH Research (NASDAQ:GHRS) shares decreased by 16.92% to $12.3. The company's market cap stands at $640.2 million.
    • MAIA Biotechnology (AMEX:MAIA) shares declined by 16.23% to $3.15. The market value of their outstanding shares is at $68.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BGXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGXX
    $CCM
    $CSBR
    $CVRX

    CompanyDatePrice TargetRatingAnalyst
    Rezolute Inc.
    $RZLT
    3/25/2026$5.00Neutral → Outperform
    Wedbush
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    GH Research PLC
    $GHRS
    10/13/2025$19.00Buy
    Needham
    GH Research PLC
    $GHRS
    6/4/2025$25.00Overweight
    Cantor Fitzgerald
    CVRx Inc.
    $CVRX
    5/9/2025$7.00Neutral → Underweight
    Analyst
    GH Research PLC
    $GHRS
    3/13/2025$32.00Buy
    Guggenheim
    More analyst ratings

    $BGXX
    $CCM
    $CSBR
    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FibroBiologics Announces Closing of $3 Million Public Offering

    HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,272,728 shares of common stock (the "Warrants"), at a combined public offering price of $1.32 per share (or per common stock equivalent in lieu t

    4/2/26 4:01:00 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Announces Pricing of $3 Million Public Offering

    HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the pricing of a best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,272,728 shares of common stock (the "Warrants"), at a combined public offering price of $1.32 per share (or per common stock equivalent in lieu thereof) and accompanyin

    3/31/26 8:00:00 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

    HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the successful completion of manufacturing of the first batch of FibroBiologics' proprietary CYWC628 drug product that will support upcoming first-in-human clinical trials. Manufactured in accordance with Food and Drug Administration's (FDA's) Good Manufacturing Practices (CGMP), the drug product will be released after it successfully passes all required safety a

    3/31/26 4:15:00 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $CCM
    $CSBR
    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Cameron Aaron Luke

    3 - GH Research PLC (0001855129) (Issuer)

    4/2/26 5:52:09 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hanley Dermot John

    3 - GH Research PLC (0001855129) (Issuer)

    4/2/26 5:39:14 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Halle Magnus Clemensen

    3 - GH Research PLC (0001855129) (Issuer)

    4/2/26 5:35:50 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $CCM
    $CSBR
    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rezolute upgraded by Wedbush with a new price target

    Wedbush upgraded Rezolute from Neutral to Outperform and set a new price target of $5.00

    3/25/26 8:24:55 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $CCM
    $CSBR
    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/5/26 8:00:15 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/4/26 5:50:10 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    3/3/26 8:00:20 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $CCM
    $CSBR
    $CVRX
    SEC Filings

    View All

    $BGXX
    $CCM
    $CSBR
    $CVRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FibroBiologics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - FibroBiologics, Inc. (0001958777) (Filer)

    4/3/26 4:02:47 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    4/2/26 4:15:32 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Silo Pharma, Inc. (0001514183) (Filer)

    4/2/26 4:15:09 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BGXX
    $CCM
    $CSBR
    $CVRX
    Leadership Updates

    Live Leadership Updates

    View All

    Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

    REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. "We're thrilled to welcome Sunil to our leadership team at such a pivotal point as we advance ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "His proven track record of successfully bringing therapies to patients across multiple therapeutic areas, including four ultr

    8/20/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update. Recent Highlights Successfully closed third $5 million tranche of a $25 million total financing, with proceeds used to advance research and development efforts and support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs).Strengthened leadership team with the appointment of

    7/31/25 4:30:00 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $CCM
    $CSBR
    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GH Research PLC

    SC 13G/A - GH Research PLC (0001855129) (Subject)

    11/14/24 5:46:11 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 10:04:23 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $CCM
    $CSBR
    $CVRX
    Financials

    Live finance-specific insights

    View All

    CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarterTotal revenue for 2025 was $56.7 million, an increase of 10% over the prior yearActive implanting centers

    2/12/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

    MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone

    1/29/26 4:10:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

    Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI). The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self

    12/11/25 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care